Cynata Reports Positive 28-Day Data From Cohort B Of Phase 1 Trial Of CYP-001 In GVHD

June 21 (Reuters) - Cynata Therapeutics Ltd (CYP) :

  • CYNATA REPORTS POSITIVE 28-DAY DATA FROM COHORT B OF PHASE 1 TRIAL OF CYP-001 IN GVHD
  • CYNATA THERAPEUTICS - NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS OR SAFETY CONCERNS HAVE BEEN IDENTIFIED IN PHASE 1 CLINICAL TRIAL OF CYP-001


To read reuters' full disclaimer click here
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.